



**World Health  
Organization**

INN Working Document 12.313

15/06/2012

**Addendum<sup>1</sup> 1 to**  
***"The use of stems in the selection of International  
Nonproprietary names (INN) for pharmaceutical  
substances"*** WHO/EMP/QSM/2011.3

***Programme on International Nonproprietary Names (INN)***

***Quality Assurance and Safety: Medicines (QSM)***

***World Health Organization, Geneva***

© World Health Organization 2012 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

*This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.*

## Addendum<sup>1</sup> 1 to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/QSM/2011.3

<sup>1</sup> This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2011.

---

-tibant	bradykinin receptor antagonists
	anatibant (88), deltibant (75), fasitibant chloride (103), icatibant (67), safotibant (105)

---

---

-zomib	proteasome inhibitors
	bortezomib (88), carfilzomib (97), delanzomib (105), ixazomib (104), marizomib (102)

---

### Update of the Annex 4 (new infixes are underlined)

## INNs FOR GENE THERAPY PRODUCTS

The following nomenclature scheme was adopted by the members of the INN Expert Group designated to deal with the selection of nonproprietary names in December 2005 after a broad consultative process.

A two-word name approach has been selected:

<b>Word 1</b>	<b>-gene</b>	<i>gene component</i>
	<del>-cima-</del>	<u>cytosine deaminase</u>
	<del>-ermin-</del>	growth factor
	<del>-kin-</del>	interleukin
	<del>-lim-</del>	immunomodulator
	<del>-lip-</del>	<u>human lipoprotein lipase</u>
	<del>-mul-</del>	multiple gene
	<del>-stim-</del>	<u>colony stimulating factor</u>
	<del>-tima-</del>	<u>thymidine kinase</u>
	<del>-tusu-</del>	tumour suppression

prefix	infix		suffix
random to contribute to euphonious and distinctive name	- <u>cima</u> - - <u>ermin</u> - - <u>kin</u> - - <u>mul</u> - - <u>lim</u> - - <u>lip</u> - - <u>stim</u> - - <u>tima</u> - - <u>tusu</u> - etc.	<u>cytosine deaminase</u> growth factors interleukins multiple genes immunomodulators human lipoprotein lipase <u>colony stimulating factor</u> <u>thymidine kinase</u> tumour suppression	-(a vowel) <u>gene</u> e.g. -(o) <u>gene</u>

## Word 2

-vec	vector component is a virus
-repvec	replicating viral vector
-adeno-	adenovirus
-cana-	canarypox virus
- <u>foli</u> -	<u>fowlpox virus</u>
-herpa-	herpes virus
-lenti-	lentivirus
-morbilli-	paramoxyviridae morbillivirus
-parvo-	adeno-associated virus (parvoviridae dependovirus)
-retro-	other retrovirus
-vaci-	vaccinia virus
-plasmid	in case the vector is a plasmid

prefix	infix		suffix	
random to contribute to euphonious and distinctive name	-adeno- -cana- - <u>foli</u> - -herpa- -lenti- -morbilli- -parvo-	adenovirus canarypox virus fowlpox virus herpes virus lentivirus paramoxyviridae morbillivirus adeno-associated virus	-vec  -repvec	virus  replicating viral vector

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28150](https://www.yunbaogao.cn/report/index/report?reportId=5_28150)

